TLR9 and leukemia: Furthermore, treatment of ALL-bearing mice with CpG ODN, an agonist for TLR9, induced significant immune-mediated killing of human leukemia cells [26] and achieved durable T cell-dependent protection against outgrowth of transplanted syngeneic B-ALL cell lines [27].